

INSTRUCTIONS FOR PATIENTS REQUESTING PAXLOVID:

Paxlovid is an effective and well-tolerated oral treatment for first-line therapy for patients age 12 and older with mild to moderate COVID-19 infection who are at risk for developing more serious illness and hospitalization. Paxlovid does, however, have various pharmacologic and drug interactions AND potential contraindications. Therefore, prescribing this medication requires, at a minimum, a televisit visit with an FMAR provider to review your medical history, your current medications, and current (within 6 months) lab tests for liver and kidney function. Co-pays and deductibles apply to your televisit. However, the drug is currently free to eligible patients with a prescription.

The FDA has issued an emergency use authorization (EUA) (SEE EUA HERE; <https://www.fda.gov/media/155051/download>) for Paxlovid individuals who meet the following criteria:

- 1) Test positive for COVID-19 – on an FDA -authorized NAA test – including a home test kit.
- 2) Age 12 and older and weigh at least 88 lbs.
- 3) Are 65 and older or have a medical condition that increases your risk for severe COVID-19 such as pregnancy, chronic illnesses such as diabetes and obesity, or are immune compromised.
- 4) Have mild to moderate symptoms
- 5) Can start treatment within 5 days of symptoms onset
- 6) Are not hospitalized when the treatment with Paxlovid is initiated.

If you have a positive COVID-19 test and meet these criteria listed above you should call our office for an appointment as soon as possible. This appointment should be scheduled during regular office hours between 7:30 am and 5 pm. Prescriptions for Paxlovid will not be filled outside of regular office hours except in situations where waiting would put you outside of the timeframe required. You must be able to provide a picture or printout of your positive COVID-19 test and provide a complete list of any prescribed medications, supplements, over-the-counter, and recreational drugs you are taking or have recently taken so that your provider can evaluate the potential for drug-to-drug interactions.